Telpegfilgrastim for Chemotherapy-induced Neutropenia in Breast Cancer: A Multicenter, Randomized, Phase 3 study
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Shi Y, Chen Q, Zhu Y, He X, Wang H, Jiang Z
. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study. Anticancer Drugs. 2013; 24(6):641-7.
DOI: 10.1097/CAD.0b013e3283610b5d.
View
2.
Blease C, Bernstein M, Locher C
. Open-label placebo clinical trials: is it the rationale, the interaction or the pill?. BMJ Evid Based Med. 2019; 25(5):159-165.
PMC: 6930978.
DOI: 10.1136/bmjebm-2019-111209.
View
3.
Green M, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P
. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2002; 14(1):29-35.
DOI: 10.1093/annonc/mdg019.
View
4.
Xu F, Zhang Y, Miao Z, Zeng X, Wu B, Cai L
. Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial. Ann Transl Med. 2019; 7(18):482.
PMC: 6803220.
DOI: 10.21037/atm.2019.07.95.
View
5.
Barbosa C Rocha F, Falcone A, Buzaid A, Pimenta J, Schvartsman G, Frasson A
. Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018. Breast Cancer Res Treat. 2018; 172(2):265-272.
DOI: 10.1007/s10549-018-4912-x.
View